DDInter9 DDInter1435
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Acalabrutinib {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Acalabrutinib {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Acalabrutinib may lead to a major life threatening interaction when taken with Idelalisib
Acalabrutinib may lead to a major life threatening interaction when taken with Binimetinib
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Acalabrutinib may lead to a major life threatening interaction when taken with Flurbiprofen